Evaluation of the combined effect of pranlukast during high-dose steroid inhalation

Takahiko Horiguchi; Soichi Tachikawa; Rieko Kondo; Junichi Miyazaki; Yasushi Sasaki; Kengo Banno; Misuzu Handa

doi:10.1055/s-0031-1299972

Evaluation of the combined effect of pranlukast during high-dose steroid inhalation

Takahiko Horiguchi, Soichi Tachikawa, Rieko Kondo, Junichi Miyazaki, Yasushi Sasaki, Kengo Banno, Misuzu Handa

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

In 40 patients with moderate to severe persistent adult asthma who had been requiring more than 1200 μg/day of beclomethasone dipropionate (CAS 5534-09-8, BDP) inhalation, the present study evaluated the combined effects of pranlukast (CAS 103177-37-3, Onon®) during high-dose steroid inhalation (20 in the pranlukast group and 20 in the control group). In the pranlukast group, 450 mg/day of pranlukast was administered. The course of these patients was monitored for 6 weeks during which the dose of BDP was decreased to 1/2 of the initial dose 2 weeks later and to 1/4 of the initial dose additional 4 weeks later. The dose of BDP was also decreased in the control group. The concomitant use of pranlukast significantly improved asthmatic symptoms and respiratory functions in asthmatic patients receiving high-dose steroid inhalation. Furthermore, the concomitant use of pranlukast significantly inhibited worsening of asthmatic symptoms, respiratory functions and parameters, which are frequently observed when the dose of inhalation steroids is decreased.

Original language	English
Pages (from-to)	813-816
Number of pages	4
Journal	Arzneimittel-Forschung/Drug Research
Volume	52
Issue number	11
DOIs	https://doi.org/10.1055/s-0031-1299972
Publication status	Published - 2002
Externally published	Yes

All Science Journal Classification (ASJC) codes

Drug Discovery

Access to Document

10.1055/s-0031-1299972

Fingerprint Dive into the research topics of 'Evaluation of the combined effect of pranlukast during high-dose steroid inhalation'. Together they form a unique fingerprint.

Cite this

@article{24880003aa8a4a36bf7c233cbc3eec83,

title = "Evaluation of the combined effect of pranlukast during high-dose steroid inhalation",

abstract = "In 40 patients with moderate to severe persistent adult asthma who had been requiring more than 1200 μg/day of beclomethasone dipropionate (CAS 5534-09-8, BDP) inhalation, the present study evaluated the combined effects of pranlukast (CAS 103177-37-3, Onon{\textregistered}) during high-dose steroid inhalation (20 in the pranlukast group and 20 in the control group). In the pranlukast group, 450 mg/day of pranlukast was administered. The course of these patients was monitored for 6 weeks during which the dose of BDP was decreased to 1/2 of the initial dose 2 weeks later and to 1/4 of the initial dose additional 4 weeks later. The dose of BDP was also decreased in the control group. The concomitant use of pranlukast significantly improved asthmatic symptoms and respiratory functions in asthmatic patients receiving high-dose steroid inhalation. Furthermore, the concomitant use of pranlukast significantly inhibited worsening of asthmatic symptoms, respiratory functions and parameters, which are frequently observed when the dose of inhalation steroids is decreased.",

author = "Takahiko Horiguchi and Soichi Tachikawa and Rieko Kondo and Junichi Miyazaki and Yasushi Sasaki and Kengo Banno and Misuzu Handa",

year = "2002",

doi = "10.1055/s-0031-1299972",

language = "English",

volume = "52",

pages = "813--816",

journal = "Drug Research",

issn = "2194-9379",

publisher = "Thieme",

number = "11",

}

TY - JOUR

T1 - Evaluation of the combined effect of pranlukast during high-dose steroid inhalation

AU - Horiguchi, Takahiko

AU - Tachikawa, Soichi

AU - Kondo, Rieko

AU - Miyazaki, Junichi

AU - Sasaki, Yasushi

AU - Banno, Kengo

AU - Handa, Misuzu

PY - 2002

Y1 - 2002

N2 - In 40 patients with moderate to severe persistent adult asthma who had been requiring more than 1200 μg/day of beclomethasone dipropionate (CAS 5534-09-8, BDP) inhalation, the present study evaluated the combined effects of pranlukast (CAS 103177-37-3, Onon®) during high-dose steroid inhalation (20 in the pranlukast group and 20 in the control group). In the pranlukast group, 450 mg/day of pranlukast was administered. The course of these patients was monitored for 6 weeks during which the dose of BDP was decreased to 1/2 of the initial dose 2 weeks later and to 1/4 of the initial dose additional 4 weeks later. The dose of BDP was also decreased in the control group. The concomitant use of pranlukast significantly improved asthmatic symptoms and respiratory functions in asthmatic patients receiving high-dose steroid inhalation. Furthermore, the concomitant use of pranlukast significantly inhibited worsening of asthmatic symptoms, respiratory functions and parameters, which are frequently observed when the dose of inhalation steroids is decreased.

AB - In 40 patients with moderate to severe persistent adult asthma who had been requiring more than 1200 μg/day of beclomethasone dipropionate (CAS 5534-09-8, BDP) inhalation, the present study evaluated the combined effects of pranlukast (CAS 103177-37-3, Onon®) during high-dose steroid inhalation (20 in the pranlukast group and 20 in the control group). In the pranlukast group, 450 mg/day of pranlukast was administered. The course of these patients was monitored for 6 weeks during which the dose of BDP was decreased to 1/2 of the initial dose 2 weeks later and to 1/4 of the initial dose additional 4 weeks later. The dose of BDP was also decreased in the control group. The concomitant use of pranlukast significantly improved asthmatic symptoms and respiratory functions in asthmatic patients receiving high-dose steroid inhalation. Furthermore, the concomitant use of pranlukast significantly inhibited worsening of asthmatic symptoms, respiratory functions and parameters, which are frequently observed when the dose of inhalation steroids is decreased.

UR - http://www.scopus.com/inward/record.url?scp=0036440506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036440506&partnerID=8YFLogxK

U2 - 10.1055/s-0031-1299972

DO - 10.1055/s-0031-1299972

M3 - Article

C2 - 12489251

AN - SCOPUS:0036440506

VL - 52

SP - 813

EP - 816

JO - Drug Research

JF - Drug Research

SN - 2194-9379

IS - 11

ER -

Evaluation of the combined effect of pranlukast during high-dose steroid inhalation

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this